Rekvina Laboratories Limited Stock

Stocks

VINRKLB

INE092O01028

Market Closed - Bombay S.E. 08:02:20 26/08/26 pm AEST			5-day change	1st Jan Change
46.90 ^INR	+1.98%		+12.47%	+942.22%

14/08	Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
13/08	Rekvina Laboratories Limited Announces Appointment of Surbhit Shah as Chairman of the Board	CI

Valuation: Rekvina Laboratories Limited

Market Cap	218M 2.29M 1.96M 1.84M 1.68M 3.16M 3.2M 21.65M 8.43M 110M 8.58M 8.4M 364M	P/E 2024	-167x	P/E 2025	-19.6x
Enterprise Value	220M 2.31M 1.98M 1.85M 1.69M 3.2M 3.23M 21.87M 8.51M 111M 8.67M 8.48M 368M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	-	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Rekvina Laboratories Limited

Dynamic Chart

Latest news : Rekvina Laboratories Limited

14/08	Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
13/08	Rekvina Laboratories Limited Announces Appointment of Surbhit Shah as Chairman of the Board	CI
14/07	Surbhit Mukesh Shah, the managing director of Rekvina Laboratories Limited, Amit Mukesh Shah, the director of Rekvina Laboratories Limited and Dhruvalkumar Patel completed the acquisition of an additional 23.22% stake in Rekvina Laboratories Limited for INR 14.41 million.	CI
22/05	Rekvina Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
16/03	Rekvina Laboratories Limited entered into agreement to acquire Radiant Parenterals Limited from Surbhit Mukesh Shah, Amit Mukesh Shah, Dhruvalkumar Patel, Krima Surbhit Shah and Ami Amit Shah for approximately INR 140 million.	CI
16/03	Surbhit Mukesh Shah and Amit Mukesh Shah, the directors of Rekvina Laboratories Limited and Dhruvalkumar Patel proposed to acquire an additional 47.94% stake in Rekvina Laboratories Limited for INR 28.9 million.	CI
11/03	Rekvina Laboratories Limited announced that it expects to receive INR 4.6 million in funding	CI
06/02	Rekvina Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
29/01	Rekvina Laboratories Limited Announces the Resignation of Chetanbhai Jayantibhai Patel as Non- Executive Independent Director and from Membership in Various Committees, Effective from 29 January 2026	CI
09/01	Rekvina Laboratories Limited Announces Resignation of Dhruvalkumar Jayantilal Patel as Non-Executive Independent Director, Effective January 9, 2026	CI
14/11	Rekvina Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
20/09/25	Rekvina Laboratories Limited Announces Shifting of the Registered Office	CI
13/08/25	Rekvina Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI

More news

Quotes and Performance

1 day	+1.98%
1 week	+12.47%
Current month	+87.60%
1 month	+85.23%
3 months	+16.81%
6 months	+76.25%
Current year	+942.22%

More quotes

Price Extremes

1 week	39.62	46.9
1 month	25	46.9
Current year	6.75	46.9
1 year	6.75	46.9
3 years	6.75	46.9
5 years	3.8	46.9
10 years	3.6	46.9

More quotes

Managers and Directors: Rekvina Laboratories Limited

Manager	Title	Age	Since
Amit Mukeshbhai Shah CEO	Chief Executive Officer	44	22/05/2024
Surbhit Shah DFI	Director of Finance/CFO	42	02/09/2024
Deepak Khandelwal CMP	Compliance Officer	-	04/12/2024

Director	Title	Age	Since
Amit Mukeshbhai Shah BRD	Director/Board Member	44	01/08/2000
Nilesh Harkesh Yadav BRD	Director/Board Member	24	22/05/2024
Surbhit Shah BRD	Director/Board Member	42	02/09/2024

More insiders

Financials

	2024	2025
Net sales	-	-
Net income	-164K -1.72K -1.47K -1.38K -1.26K -2.38K -2.4K -16.29K -6.34K -82.74K -6.46K -6.32K -274K	-1.37M -14.38K -12.32K -11.55K -10.55K -19.91K -20.1K -136K -53.02K -692K -54K -52.82K -2.29M
Net Debt	798K 8.37K 7.17K 6.72K 6.14K 11.59K 11.7K 79.28K 30.86K 403K 31.43K 30.74K 1.33M	2.22M 23.27K 19.94K 18.68K 17.06K 32.2K 32.52K 220K 85.78K 1.12M 87.36K 85.45K 3.71M